LIANY · LianBio · Insider Trading

Represents securities held by Konstanin Poukalov. Mr. Poukalov is affiliated with the Advisor. The Advisor may be deemed to have an indirect pecuniary interest in the securities of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Poukalov's board service through a partial management fee offset.

Represents securities held by Adam Stone. Mr. Stone is the Chief Investment Officer of Perceptive Advisors, LLC (the "Advisor"). The Advisor may be deemed to have an indirect pecuniary interest in the securities of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Stone's board service through a partial management fee offset.

Represents securities held by Adam Stone. Mr. Stone is the Chief Investment Officer of Perceptive Advisors, LLC (the "Advisor"). The Advisor may be deemed to have an indirect pecuniary interest in the securities of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Stone's board service through a partial management fee offset.

Represents securities held by Konstanin Poukalov. Mr. Poukalov is affiliated with the Advisor. The Advisor may be deemed to have an indirect pecuniary interest in the securities of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Poukalov's board service through a partial management fee offset.

Represents securities held by Adam Stone. Mr. Stone is the Chief Investment Officer of Perceptive Advisors, LLC (the "Advisor"). The Advisor may be deemed to have an indirect pecuniary interest in the securities of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Stone's board service through a partial management fee offset.

The shares underlying the option became exercisable in full on June 23, 2023.

Represents securities held by Konstanin Poukalov. Mr. Poukalov is affiliated with the Advisor. The Advisor may be deemed to have an indirect pecuniary interest in the securities of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Poukalov's board service through a partial management fee offset.

The shares underlying the option became exercisable in full on June 23, 2023.

Represents the sale of shares to cover personal income tax obligations upon vesting of restricted share units ('RSUs') as required pursuant to the terms of Ms. Gu's RSU award agreement. 41,078 RSUs were granted to Ms. Gu under the LianBio 2021 Equity Incentive Plan (the 'Plan') on December 31, 2021, 25% of which vested on each of December 31, 2022 and 2023 with the remainder to vest in 25% annual installments and to be fully vested on December 31, 2025, subject to Ms. Gu's providing continuous service to the Issuer on each such date. On March 22, 2024, the board of directors of the Issuer resolved to terminate the Plan and any unvested RSUs granted thereunder in accordance with the terms of the Plan, effective as of March 24, 2024. In accordance with this determination, 58,873 unvested RSUs previously reported as beneficially owned by Ms. Gu were cancelled. Ms. Gu received no value in exchange for the cancellation of the unvested RSUs.

The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date.

The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date.

The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to Konstantin Poukalov providing continuous service to the Issuer through such date.

Consists of options to purchase shares of the Issuer's ordinary shares awarded to Mr. Poukalov in connection with his role as a member of the Issuer's Board of Directors. Mr. Poukalov is affiliated with the Advisor. The Advisor may be deemed to have an indirect pecuniary interest in the options to purchase ordinary shares of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Poukalov's board service through a partial management fee offset.

Joseph Edelman is the managing member of the Advisor. The Advisor serves as the investment manager of Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Each of Mr. Edelman, the Master Fund and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of the securities reported on this form, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman, the Master Fund or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date.

The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date.

The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to Adam Stone providing continuous service to the Issuer through such date.

Consists of options to purchase shares of the Issuer's ordinary shares awarded to Mr. Stone in connection with his role as a member of the Issuer's Board of Directors. Mr. Stone is the Chief Investment Officer of Perceptive Advisors, LLC (the "Advisor"). The Advisor may be deemed to have an indirect pecuniary interest in the options to purchase ordinary shares of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Stone's board service through a partial management fee offset.

Joseph Edelman is the managing member of the Advisor. The Advisor serves as the investment manager of Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Each of Mr. Edelman, the Master Fund and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of the securities reported on this form, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman, the Master Fund or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date.

Represents restricted share units granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan. Each restricted share unit represents the contingent right to receive one share of the Issuer's Ordinary Shares. 25% of the restricted share units shall vest on March 29, 2024; the remainder shall vest in 25% annual installments such that the restricted share units are fully vested on March 29, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date.

Represents restricted share units granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan. Each restricted share unit represents the contingent right to receive one share of the Issuer's Ordinary Shares. 25% of the restricted share units shall vest on March 29, 2024; the remainder shall vest in 25% annual installments such that the restricted share units are fully vested on March 29, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date.

Represents restricted share units granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan. Each restricted share unit represents the contingent right to receive one share of the Issuer's Ordinary Shares. 25% of the restricted share units shall vest on March 29, 2024; the remainder shall vest in 25% annual installments such that the restricted share units are fully vested on March 29, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date.

Represents restricted share units granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan. Each restricted share unit represents the contingent right to receive one share of the Issuer's Ordinary Shares. 25% of the restricted share units shall vest on March 29, 2024; the remainder shall vest in 25% annual installments such that the restricted share units are fully vested on March 29, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date.

25% of the shares underlying the option will vest and become exercisable on January 20, 2024; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on January 20, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date.

25% of the shares underlying the option will vest and become exercisable on January 20, 2024; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on January 20, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date.

25% of the shares underlying the option will vest and become exercisable on January 20, 2024; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on January 20, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date.

25% of the shares underlying the option will vest and become exercisable on January 20, 2024; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on January 20, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date.

Sale of shares to cover personal income tax obligations upon vesting of restricted share units as required pursuant to the terms of Mr. Qian's restricted share unit award agreement.

Each American Depositary Share represents one Ordinary Share of the Issuer.

The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

The shares underlying the option shall vest and become exercisable in full on June 23, 2023, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date.

The shares underlying the option shall vest and become exercisable in full on June 23, 2023, the first anniversary of the grant date, subject to Konstantin Poukalov providing continuous service to the Issuer through such date.

Consists of options to purchase shares of the Issuer's ordinary shares awarded to Adam Stone in connection with his role as a member of the Issuer's Board of Directors. Mr. Stone is the Chief Investment Officer of Perceptive Advisors, LLC (the "Advisor"). The Advisor may be deemed to have an indirect pecuniary interest in the options to purchase ordinary shares of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Stone's board service through a partial management fee offset.

Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of the securities reported on this form, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

The shares underlying the option shall vest and become exercisable in full on June 23, 2023, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date.

The shares underlying the option shall vest and become exercisable in full on June 23, 2023, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date.

The shares underlying the option shall vest and become exercisable in full on June 23, 2023, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date.

The shares underlying the option shall vest and become exercisable in full on June 23, 2023, the first anniversary of the grant date, subject to Adam Stone providing continuous service to the Issuer through such date.

Consists of options to purchase shares of the Issuer's ordinary shares awarded to Konstantin Poukalov in connection with his role as a member of the Issuer's Board of Directors. Mr. Poukalov is affiliated with the Advisor. The Advisor may be deemed to have an indirect pecuniary interest in the options to purchase ordinary shares of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Poukalov's board service through a partial management fee offset.

Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of the securities reported on this form, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.065 to $3.20, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.

Each American Depositary Share represents one Ordinary Share of the Issuer.

The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.49 to $2.70, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.

Each American Depositary Share represents one Ordinary Share of the Issuer.

The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.36 to $2.53, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.

Each American Depositary Share represents one Ordinary Share of the Issuer.

The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.46 to $2.51, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.

Each American Depositary Share represents one Ordinary Share of the Issuer.

The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

1/3 of the shares underlying the option vested and became exercisable on January 1, 2020; 1/3 of the shares underlying the option vested and became exercisable on October 1, 2020 and 1/3 of the shares underlying the option vested and became exercisable on October 1, 2021, subject to the Reporting Person providing continuous service to the Issuer on each such date.

1/36 of the shares underlying the option will become exercisable on 05/06/2022; the remainder shall vest and become exercisable in 35 equal monthly installments such that the option shall be fully vested on 04/06/2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.